Table 8

Univariate sensitivity analysis

Parameters

ICER per LY (€)

ICER per QALY (€)

Palivizumab dosage scheme

Total

25,352.07

14,129.26

BPD

12,532.56

7,902.66

< 33 weeks

30,387.26

15,936.20

33–35 weeks

40,857.49

21,476.58

Annual mean cost per patient with recurrent wheezing

Total

15,437.90 – 15,699.62

8,603.88 – 8,749.74

BPD

4,225.56 – 4,438.94

2,664.51 – 2,799.06

< 33 weeks

17,717.48 – 18,054.36

9,291.70 – 9,468.37

33–35 weeks

28,248.76 – 28,585.65

14,848.85 – 15,025.93

Probability of developing recurrent wheezing within 24 months from enrollment

Total

15,857.51

8,837.74

BPD

4,577.05

2,886.15

< 33 weeks

18,253.99

9,573.06

33–35 weeks

28,782.64

15,129.48

Chirico et al. Italian Journal of Pediatrics 2009 35:4   doi:10.1186/1824-7288-35-4